Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $39.00 Consensus PT from Analysts

Akero Therapeutics, Inc. (NASDAQ:AKRO) has been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $37.71.

A number of brokerages recently commented on AKRO. HC Wainwright increased their price target on Akero Therapeutics from $40.00 to $43.00 and gave the company a “buy” rating in a report on Friday, March 1st. UBS Group lifted their price objective on shares of Akero Therapeutics from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. Finally, Bank of America initiated coverage on Akero Therapeutics in a research report on Monday. They set a “neutral” rating and a $30.00 price target for the company.

Insider Buying and Selling

In related news, COO Jonathan Young sold 5,000 shares of Akero Therapeutics stock in a transaction on Monday, April 1st. The stock was sold at an average price of $24.38, for a total value of $121,900.00. Following the transaction, the chief operating officer now directly owns 263,306 shares in the company, valued at approximately $6,419,400.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Catriona Yale sold 20,646 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $35.49, for a total value of $732,726.54. Following the completion of the sale, the insider now directly owns 78,415 shares of the company’s stock, valued at $2,782,948.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jonathan Young sold 5,000 shares of Akero Therapeutics stock in a transaction on Monday, April 1st. The shares were sold at an average price of $24.38, for a total transaction of $121,900.00. Following the sale, the chief operating officer now directly owns 263,306 shares of the company’s stock, valued at approximately $6,419,400.28. The disclosure for this sale can be found here. Insiders have sold 100,646 shares of company stock worth $3,319,877 in the last ninety days. 9.69% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Headlands Technologies LLC acquired a new stake in Akero Therapeutics in the fourth quarter valued at approximately $28,000. Quarry LP lifted its position in shares of Akero Therapeutics by 40.0% in the 4th quarter. Quarry LP now owns 1,750 shares of the company’s stock worth $41,000 after acquiring an additional 500 shares during the period. Strs Ohio boosted its position in shares of Akero Therapeutics by 100.0% during the 4th quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $46,000 after acquiring an additional 1,000 shares in the last quarter. Orion Capital Management LLC acquired a new position in shares of Akero Therapeutics in the 3rd quarter worth approximately $51,000. Finally, Quest Partners LLC bought a new position in shares of Akero Therapeutics during the fourth quarter valued at $75,000.

Akero Therapeutics Stock Performance

NASDAQ:AKRO opened at $20.79 on Friday. Akero Therapeutics has a fifty-two week low of $11.25 and a fifty-two week high of $58.38. The company has a market cap of $1.44 billion, a P/E ratio of -7.29 and a beta of -0.38. The company has a quick ratio of 29.27, a current ratio of 29.27 and a debt-to-equity ratio of 0.05. The firm’s 50 day moving average is $24.75 and its two-hundred day moving average is $21.19.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.17). Analysts expect that Akero Therapeutics will post -4.06 EPS for the current year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.